Immunotherapy has emerged as a transformative treatment for melanoma, particularly when the disease spreads to distant organs like the lungs and liver. These drugs work by removing the brakes that cancer cells use to hide from the immune system, allowing the body's own defenses to recognize and destroy melanoma cells. However, the astronomical cost of these breakthrough treatments is creating a stark divide: patients with robust insurance can access life-saving therapies, while others face impossible financial barriers (Source 1, 2).

What Is Immunotherapy and How Does It Work Against Melanoma?

Immunotherapy represents a fundamentally different approach to cancer treatment compared to traditional chemotherapy. Rather than directly attacking cancer cells, immunotherapy drugs called checkpoint inhibitors remove the brakes that cancer cells use to hide from the immune system. This allows the body's own defenses to recognize and destroy melanoma cells, even when the disease has spread to the lungs, liver, brain, or other distant sites .

The most widely prescribed immunotherapy drug for melanoma is Keytruda (pembrolizumab), manufactured by Merck. The drug has become so central to cancer treatment that it generated $31.7 billion in worldwide sales in 2025, accounting for nearly half of Merck's total revenue . For many patients, Keytruda represents their best chance at survival when melanoma has advanced beyond the skin.

Why Does a Single Dose of Immunotherapy Cost More Than a House?

A single dose of Keytruda can cost patients and their insurers staggering amounts. One California patient's bill for a 400-milligram dose reached $162,567.74, though Merck's listed price for that same dose is $24,000. The difference reflects how middlemen in the healthcare system, including pharmacy benefit managers and health insurers, extract rebates and fees that drive up final costs .

Merck has employed several strategies to maintain these high prices. The company has built a fortress of 50 active patents around Keytruda in the United States alone, with more than 1,200 patent applications filed in 53 countries, regions, and territories. These patents could allow Merck to fend off generic competition for 14 years after the original patents expire in 2028, according to analysis by the International Consortium of Investigative Journalists .

Additionally, Merck is rolling out a new injectable version called Keytruda Qlex and expects 30 to 40 percent of current users to switch to this new formulation before the original patent expires. If that transition occurs, it could delay generic competition until the 2030s, extending Merck's monopoly and maintaining high prices for years longer .

How to Understand Your Immunotherapy Options and Costs

• Dosing Considerations: The FDA has approved Keytruda at two dosing schedules: 200 milligrams every three weeks or 400 milligrams every six weeks. Some cancer researchers contend that Merck promotes higher dosages than necessary, potentially costing each patient an extra $75,000 over their treatment course. The World Health Organization estimates that optimizing dosing could save $5 billion through 2040 among lung cancer patients alone.
• Insurance and Out-of-Pocket Costs: Your actual cost will depend on your insurance plan, deductible, and copay structure. A patient may owe $2,000 while the total bill to insurance reaches six figures. Ask your healthcare provider for a detailed cost breakdown before starting treatment.
• Medicare Negotiation Status: The Inflation Reduction Act gave Medicare the power to negotiate lower drug prices, but President Trump's 2025 tax legislation delayed these negotiations for some drugs, including Keytruda, by at least one year. Check with your provider about whether your coverage qualifies for any negotiated pricing.

Real-World Resilience: One Patient's Fight Against Repeated Melanoma

Dick Vitale, the legendary college basketball broadcaster, was diagnosed with melanoma in his lung and liver cavity and is immediately beginning immunotherapy treatment. At 86 years old, this is his second melanoma diagnosis, but his fifth cancer diagnosis overall, having previously overcome melanoma, lymphoma, vocal cord cancer, and lymph node cancer .

"I've beaten melanoma. I've beaten lymphoma. I've beaten vocal cord cancer. I've beaten lymph node cancer. I'm 4 for 4 and I'm fully confident I'm going to make it 5 for 5," Vitale declared in a statement released by ESPN.

Dick Vitale, ESPN Analyst

Vitale's case illustrates both the promise and the challenge of modern immunotherapy. While the treatment offers genuine hope for advanced melanoma, the financial burden remains crushing for many patients. His ability to access cutting-edge immunotherapy reflects his position as a prominent public figure with comprehensive insurance coverage, a luxury not available to all melanoma patients.

The Global Access Problem: Who Can Actually Afford Immunotherapy?

The investigation by the International Consortium of Investigative Journalists and USA TODAY found that Merck's pricing tactics have priced Keytruda out of reach for cancer patients in some countries outside the United States. In the U.S., where Merck generates about 60 percent of Keytruda's sales, prices generally begin with Merck's list price and increase from there as middlemen add charges .

Merck has defended its pricing by arguing that high costs in the U.S. are driven by pharmacy benefit managers and health insurers who extract rebates and fees. The company stated that "America is the only country in the world where entities that don't make medicines take half of every dollar spent on brand medicines." However, critics argue that Merck's patent strategy and resistance to Medicare price negotiations also play a significant role in maintaining elevated costs .

The broader context is concerning: cancer remains the top cause of death in Canada, with 254,000 new cases projected for 2026 alone. While advancements in immunotherapy and targeted treatments are helping patients live longer, these benefits are not equally distributed across all populations and income levels .

What Experts Say About the Future of Immunotherapy Pricing

"Squeezing as much life out of an original patent is par for the course in the drug industry. You get a breadwinner, you want to hold onto that breadwinner as long as you can," explained Antonio Ciaccia, president of 3 Axis Advisors and an expert in drug pricing.

Antonio Ciaccia, President of 3 Axis Advisors

The patent strategy employed by Merck is not unique to the pharmaceutical industry. According to drug pricing experts, using patents to delay competition from companies offering less expensive biosimilar versions is a common tactic. A Harvard Medical School professor noted that the existence of a patent thicket can discourage biosimilar manufacturers from entering the market, as they would need to spend enormous sums fighting patents in court .

"This scenario where a drug company obtains dozens of patents protecting different aspects of a blockbuster drug in order to ward off competition is quite common," stated Dr. Benjamin Rome, a Harvard Medical School professor. "Just the existence of this patent thicket can scare away companies who would otherwise seek to make biosimilar versions of Keytruda, as the biosimilar makers need to spend exorbitant amounts of money to fight these patents in court."

Dr. Benjamin Rome, Harvard Medical School

Despite these barriers, immunotherapy continues to represent genuine progress for melanoma patients. The advent of checkpoint inhibitors, more targeted treatments, and a better understanding of how cancers behave are all factors making a difference for modern cancer patients. However, experts acknowledge that the healthcare system still has a long way to go in making these life-saving treatments accessible to everyone who needs them .

The challenge ahead is clear: how to preserve the innovation incentives that drive drug development while ensuring that breakthrough treatments like immunotherapy are not reserved only for the wealthy. Until that balance is struck, melanoma patients will continue to face an impossible choice between financial ruin and access to the treatments that could save their lives.